ScholarLens Back to search
2021•Frontiers in OncologyOpen access

Retraction: Combination of Tanshinone IIA and Cisplatin Inhibits Esophageal Squamous Cell Carcinoma by Down-Regulating NF-kB/COX-2/VEGF Pathway

Frontiers Editorial Office

Open full text 0 citations

Abstract

Please find the retraction statement below:Liao, X., Gao, Y., Liu, J., Tao, L., Xie, J., Gu, Y., Liu, T., Wang, D., Xie, D., & Mo, S. (2020). Combination of Tanshinone IIA and Cisplatin Inhibits Esophageal Cancer by Downregulating NF-κB/COX-2/VEGF Pathway. Frontiers in oncology, 10, 1756. https://doi.org/10.3389/fonc.2020.01756“Following publication, concerns were raised regarding the integrity of the images in the published figures. The authors failed to provide a satisfactory explanation during the investigation, which was conducted in accordance with Frontiers’ policies.This retraction was approved by the Chief Editors of Frontiers in Oncology and the Chief Executive Editor of Frontiers. The authors did not agree to this retraction."

Open-access reader

About this research paper

What this paper is about

Please find the retraction statement below:Liao, X., Gao, Y., Liu, J., Tao, L., Xie, J., Gu, Y., Liu, T., Wang, D., Xie, D., & Mo, S. (2020). Combination of Tanshinone IIA and Cisplatin Inhibits Esophageal Cancer by Downregulating NF-κB/COX-2/VEGF Pathway. Frontiers in oncology, 10, 1756. https://doi.org/10.3389/fonc.2020.01756“Following publication, concerns were raised regarding the integrity of the images in the published figures. The authors failed to provide a satisfactory explanation during the investigation, which was conducted in accordance with Frontiers’ policies.This retraction was approved by the Chief Editors of Frontiers in Oncology and the Chief Executive Editor of Frontiers. The authors did not agree to this retraction."

Why it matters

A significance statement is not available in the OpenAlex record.

Key contribution

A contribution statement is not available in the OpenAlex record.

Method / approach

Method details are not available in the OpenAlex metadata.

Main findings

Findings are not separately available in the OpenAlex metadata.

Limitations

Limitations are not available in the OpenAlex metadata.

Applications

Application details are not available in the OpenAlex metadata.

Available abstract

Please find the retraction statement below:Liao, X., Gao, Y., Liu, J., Tao, L., Xie, J., Gu, Y., Liu, T., Wang, D., Xie, D., & Mo, S. (2020). Combination of Tanshinone IIA and Cisplatin Inhibits Esophageal Cancer by Downregulating NF-κB/COX-2/VEGF Pathway. Frontiers in oncology, 10, 1756. https://doi.org/10.3389/fonc.2020.01756“Following publication, concerns were raised regarding the integrity of the images in the published figures. The authors failed to provide a satisfactory explanation during the investigation, which was conducted in accordance with Frontiers’ policies.This retraction was approved by the Chief Editors of Frontiers in Oncology and the Chief Executive Editor of Frontiers. The authors did not agree to this retraction."

Key concepts: Cisplatin, Esophageal squamous cell carcinoma, Cancer research, Esophageal cancer, VEGF receptors, Medicine, Basal cell, Oncology

Related papers

Related paper 1Related paper 2Related paper 3
Back to paper searchBrowse research topicsOriginal source
Retraction: Combination of Tanshinone IIA and Cisplatin Inhibits Esophageal Squamous Cell Carcinoma by Down-Regulating NF-kB/COX-2/VEGF Pathway — Research Paper | ScholarLens